(RNGR) Movement as an Input in Quant Signal Sets

Ranger Energy Services, Inc. (RNGR) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposition of Assets As previously disclosed in the Current Report on Form 8-K filed by Ranger Energy Services, Inc., (the “Company”) on August 31, 2026, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with S

Ranger Energy Services, Inc. (RNGR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rngr-063026ex991earningsre.htm EX-99.1 Document EXHIBIT 99.1 Ranger Energy Services, Inc. Reports Second Quarter 2026 Financial Results HOUSTON, TX — (July 27, 2026) — Ranger Energy Services, Inc. (NYSE: RNGR) (“Ranger” or the “Company”) today reported its financial and

Kroger (KR) plans to invest $5 billion by 2029 to lower prices, aiming to compete with Walmart (WMT) and Costco (COST). The company expects to achieve $4 billion in annualized cost savings by 2029, with half from cost of goods. Kroger also announced cuts to about a third of its corporate roles. The stock saw volatility post-announcement, closing at $64.13 on October 21. Analysts have adjusted price targets, with Deutsche Bank at $70, Guggenheim at $68, UBS at $66, and Wells Fargo at $60.

Wedbush Securities raised its price target for SentinelOne (NYSE:S) to $27 from $25, citing the company's AI investments and broader security infrastructure. Analyst Steven Wahrhaftig reiterated an Outperform rating, noting customer expansion beyond endpoint security and competitive pricing advantages over CrowdStrike. Wedbush believes SentinelOne is positioning itself well for future growth.

Hudbay Minerals approved the Copper World project in Arizona, with RBC and Scotiabank supporting the move. The project could boost copper production to over 200,000 tonnes by 2030, according to RBC. Scotiabank noted improved production profiles and reduced risks. Both banks maintained positive ratings and price targets for Hudbay.

Biohaven (BHVN) +31% after FDA accepted resubmitted drug application for spinocerebellar ataxia. Korro Bio (KRRO) +25% on positive preclinical results for AATD treatment. Actinium (ATNM) +18% with initial Phase 1 data for prostate cancer radiotherapy. Vicore (VCRE) +16% after passing IPF trial futility analysis.